Zoetis Inc. (NYSE:ZTS) Shares Sold by Keybank National Association OH

Keybank National Association OH lowered its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 7.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 216,016 shares of the company's stock after selling 17,219 shares during the quarter. Keybank National Association OH's holdings in Zoetis were worth $35,567,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mission Wealth Management LP grew its stake in shares of Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after buying an additional 59 shares during the period. HUB Investment Partners LLC lifted its holdings in Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after acquiring an additional 62 shares during the last quarter. Coppell Advisory Solutions LLC lifted its holdings in Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after acquiring an additional 64 shares during the last quarter. Lindbrook Capital LLC grew its position in Zoetis by 1.8% in the fourth quarter. Lindbrook Capital LLC now owns 3,650 shares of the company's stock worth $595,000 after acquiring an additional 65 shares during the period. Finally, Ironwood Investment Management LLC increased its stake in Zoetis by 0.8% during the fourth quarter. Ironwood Investment Management LLC now owns 8,354 shares of the company's stock worth $1,361,000 after acquiring an additional 68 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.18% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research analyst reports. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. UBS Group cut their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Finally, Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $212.13.

Zoetis Trading Up 0.1%

Shares of NYSE ZTS traded up $0.11 during trading on Friday, reaching $159.19. The stock had a trading volume of 1,375,164 shares, compared to its average volume of 2,569,728. The company has a market cap of $70.87 billion, a P/E ratio of 28.58, a PEG ratio of 2.64 and a beta of 0.91. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. The business's 50-day moving average price is $161.16 and its 200-day moving average price is $162.12. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.38 earnings per share. On average, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.26%. Zoetis's dividend payout ratio is presently 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.